A helper cell for producing an infectious, replication defective, coronavirus (or more generally nidovirus) particle cell comprises (a) a nidovirus permissive cell; (b) a nidovirus replicon RNA comprising the nidovirus packaging signal and a heterologous RNA sequence, wherein the replicon RNA further lacks a sequence encoding at least one nidovirus structural protein; and (c) at least one separate helper RNA encoding the at least one structural protein absent from the replicon RNA, the helper RNA(s) lacking the nidovirus packaging signal. The combined expression of the replicon RNA and the helper RNA in the nidovirus permissive cell produces an assembled nidovirus particle which comprises the heterologous RNA sequence, is able to infect a cell, and is unable to complete viral replication in the absence of the helper RNA due to the absence of the structural protein coding sequence in the packaged replicon. Compositions for use in making such helper cells, along with viral particles produced from such cells, compositions of such viral particles, and methods of making and using such viral particles, are also disclosed.
From the Reiner/Martin interview:
… in 1999 Anthony Fauci funded research at the University of North Carolina Chapel Hill, specifically to create, and you cannot help but, you know, lament what I’m about to read because this comes directly from a patent application filed on April 19 2002. And you heard the date correctly 2002 where the NIAID built an infectious replication defective Coronavirus that was specifically targeted for human lung epithelium. In other words, we made SARS and we patented it on April 19 2002, before there was ever any alleged outbreak in Asia, which as you know, followed that by several months. That patent issued is US Patent 7279327. That patent clearly lays out in very specific gene sequencing, the fact that we knew that the ACE receptor, the ACE2 binding domain, the s1 spike protein, and other elements of what we have come to know as this scourge pathogen was not only engineered, but could be synthetically modified in the laboratory, using nothing more than gene sequencing technologies, taking computer code and turning it into a pathogen or an intermediate of the pathogen. And that technology was funded exclusively in the early days as a means by which we could actually harness Coronavirus as a vector to distribute HIV vaccine.
— Dr. David Martin at 02:53
To see how DNA is generated directly from a computer, see “How We Make DNA” – Cambrian Genomics.
Sources:
- October 9, 2007. Kristopher M. Curtis, Boyd Yount, and Ralph S. Baric. United States Patent: 7279327 – Methods for producing recombinant coronavirus. 7279327, filed April 19, 2002, and issued October 9, 2007. Assignee: The University of North Carolina at Chapel Hill (Chapel Hill, NC).
https://patents.google.com/patent/US7279327B2,
https://patents.justia.com/patent/7279327,
Local copy.
Patent. - July 12, 2021. “Reiner Fuellmich Interviews Dr David Martin – CDC Patent Fraud.” Covid Truths.
https://www.covidtruths.co.uk/2021/07/reiner-fuellmich-interviews-dr-david-martin-cdc-patent-fraud/.
Blog, Video, Expert.
Includes transcript. - April 3, 2020. M•CAM International. “CoV Patent Corpus Literature Review.”
https://www.m-cam.com/wp-content/uploads/2020/04/20200403_SARS_CoV_Patent_Corpus_Lit_Review.pdf.
Expert, PDF.
See also, on this site:
- “How We Make DNA” – Cambrian Genomics
- All posts citing the 12 July 2021 interview between Reiner Fuellmich and Dr David Martin on CDC Patent Fraud